Display options
Cite
Nino A, Okuda I, Wilson TH, et al. Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. J Diabetes Investig. 2017;doi: 10.1111/jdi.12749.
Nino, A., Okuda, I., Wilson, T. H., Yue, L., Nakajima, H., Tsuboi, M., Carr, M. C., & Seino, Y. (2017). Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Journal of diabetes investigation, . https://doi.org/10.1111/jdi.12749
Nino, Antonio, et al. "Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study." Journal of diabetes investigation vol. (2017). doi: https://doi.org/10.1111/jdi.12749
Nino A, Okuda I, Wilson TH, Yue L, Nakajima H, Tsuboi M, Carr MC, Seino Y. Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. J Diabetes Investig. 2017 Sep 16; doi: 10.1111/jdi.12749. Epub 2017 Sep 16. PMID: 28921915; PMCID: PMC5934244.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Investig. 2017 Sep 16; doi: 10.1111/jdi.12749. Epub 2017 Sep 16.

Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study.

Journal of diabetes investigation

Antonio Nino, Inaha Okuda, Timothy H Wilson, Lynn Yue, Hiromu Nakajima, Maho Tsuboi, Molly C Carr, Yutaka Seino

Affiliations

  1. GlaxoSmithKline, Collegeville, PA, USA.
  2. GlaxoSmithKline, Tokyo, Japan.
  3. PAREXEL International, Durham, NC, USA.
  4. Kansai Electric Power Hospital, Osaka, Japan.

PMID: 28921915 PMCID: PMC5934244 DOI: 10.1111/jdi.12749

Abstract

AIMS/INTRODUCTION: The present phase 3, randomized, double-blind 24-week study with extension to 1 year assessed the efficacy and safety of albiglutide compared with placebo in Japanese patients with type 2 diabetes mellitus inadequately controlled by diet and exercise with or without a single oral antidiabetic drug.

MATERIALS AND METHODS: Patients received weekly albiglutide 30 mg (n = 160), albiglutide 50 mg (n = 150) or a placebo switched to albiglutide 30 mg after 24 weeks (n = 77). Open-label daily liraglutide 0.9 mg (n = 103) was included as a reference. Oral antidiabetic drug use was discontinued before baseline. The primary end-point was 24-week change from baseline in glycated hemoglobin (HbA1c). Secondary end-points included fasting plasma glucose, bodyweight and adverse events.

RESULTS: At 24 weeks, mean HbA1c changes from baseline were -1.10, -1.30, and 0.25% for albiglutide 30, 50 mg and placebo, respectively (P vs placebo <0.0001 for both albiglutide doses), -1.19% for liraglutide. Decreases in HbA1c with albiglutide were sustained through the study. Mean fasting plasma glucose decreased by ≥20 mg/dL, and the mean change in bodyweight was ≤0.5 kg through 1 year across groups. Most commonly reported adverse events were nasopharyngitis, constipation and nausea. The incidence of adverse events was higher in active treatment groups than in the placebo group. Few hypoglycemia events were reported; no patient withdrew as a result of hypoglycemia. No new safety signals were detected.

CONCLUSIONS: Albiglutide monotherapy achieved clinically significant decreases in HbA1c and fasting plasma glucose with good tolerability in Japanese patients with type 2 diabetes mellitus inadequately controlled by diet and exercise with or without a single oral antidiabetic drug.

© 2017 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Keywords: Glucagon-like peptide 1; Japan; Type 2 diabetes mellitus

References

  1. Curr Med Res Opin. 2014 Jun;30(6):1095-106 - PubMed
  2. Diabetes Obes Metab. 2014 Dec;16(12):1257-64 - PubMed
  3. J Diabetes Investig. 2012 Jun 6;3(3):271-5 - PubMed
  4. Curr Med Res Opin. 2009 Dec;25(12):3049-57 - PubMed
  5. Diabetes Care. 2014 Aug;37(8):2141-8 - PubMed
  6. Lancet Diabetes Endocrinol. 2016 Jun;4(6):525-36 - PubMed
  7. Lancet Diabetes Endocrinol. 2014 Apr;2(4):289-97 - PubMed
  8. Diabetologia. 2013 Apr;56(4):696-708 - PubMed
  9. Diabetes Obes Metab. 2014 Oct;16(10):900-9 - PubMed
  10. Diabetes Obes Metab. 2015 Feb;17(2):179-87 - PubMed
  11. Diabetologia. 2016 Feb;59(2):266-74 - PubMed
  12. Ann Pharmacother. 2012 Nov;46(11):1453-69 - PubMed
  13. Diabetologia. 2014 Dec;57(12):2475-84 - PubMed
  14. Diabetes Care. 2014 Aug;37(8):2317-25 - PubMed
  15. Metabolism. 2004 Jul;53(7):831-5 - PubMed
  16. J Diabetes Investig. 2016 Apr;7 Suppl 1:102-9 - PubMed
  17. Curr Diab Rep. 2015 Jun;15(6):602 - PubMed

Publication Types